Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Atossa Therapeutics, retaining the price target of $7.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on the promising clinical trial results of Atossa Therapeutics’ Z-endoxifen, which demonstrated superior efficacy compared to tamoxifen in treating ER+/HER2- metastatic breast cancer (mBC). The Phase 2 study highlighted that patients treated with Z-endoxifen had a significantly longer median progression-free survival (PFS) compared to those on tamoxifen, particularly in CDK4/6 inhibitor-naive patients and those with ESR1 mutations.
Additionally, early results from the RECAST DCIS trial suggest that Z-endoxifen, combined with MRI monitoring, could be a feasible alternative to surgery for ductal carcinoma in situ (DCIS), as it showed no severe adverse effects and maintained patient engagement in active surveillance. These findings indicate a potential for Z-endoxifen to address unmet needs in breast cancer treatment, supporting the Buy rating as further updates and regulatory clearances are anticipated.